Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11588944 | 0.90 | MAPT (0.43) | PTGDR2POLBKDM4ETDP1ADAMTS5 | |
| SCHEMBL4480982 | 0.83 | TDP1 (0.48) | POLBTDP1CYP1A2CXCL12MAPT | |
| SCHEMBL8545353 | 0.82 | KDM4E (0.45) | PTGDR2POLBKDM4EADAMTS5CYP1A2 | |
| SCHEMBL4477996 | 0.81 | TDP1 (0.40) | POLBTDP1CYP1A2CXCL12MAPT | |
| SCHEMBL10691153 | 0.80 | LMNA (0.48) | PTGDR2POLBKDM4ETDP1MAPT | |
| SCHEMBL10360134 | 0.79 | PTGDR2 (0.39) | PTGDR2POLBKDM4EADAMTS5CYP1A2 | |
| SCHEMBL8591973 | 0.79 | ECE1 (0.42) | PTGDR2POLBKDM4ETDP1ADAMTS5 | |
| SCHEMBL46644 | 0.78 | LMNA (0.40) | PTGDR2POLBKDM4EADAMTS5CYP1A2 | |
| SCHEMBL8545303 | 0.78 | KDM4E (0.43) | PTGDR2POLBKDM4EADAMTS5CYP1A2 | |
| SCHEMBL8547096 | 0.78 | ALOX15 (0.42) | POLBKDM4EADAMTS5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4077968-A | ANTIINFLAMMATORY, ANTIRHEUMATIC, ANALGESIC, ANTILIPEMIC | SHIONOGI & CO., LTD. (JA) | 1978-03-07 | — | — | US | claimed |
| US-7557123-B2 | Heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1403253-A1 | NOVEL HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-4077968-A | ANTIINFLAMMATORY, ANTIRHEUMATIC, ANALGESIC, ANTILIPEMIC | SHIONOGI & CO., LTD. (JA) | 1978-03-07 | — | — | US | disclosed |
| US-4025528-A | ANTIINFLAMMATORY, ANALGESIC, ANTILIPEMIC | SHIONOGI & CO., LTD. (JA) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | GPR119, INSR, GLP1R | PTGDR2 1423/4885POLB 3675/4885KDM4E 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.